Serco bemoaned “wildly unfair” criticism of its role in the much-criticised NHS Covid-19 test-and-trace scheme, as the outsourcing firm reported increased full-year profits that could fund more than £100m in shareholder rewards.
The company said it had won £700m in Covid-related contracts worldwide in 2021, taking its total pandemic-related income to £1.1bn.
